14 Questions to Ask When Starting Immunotherapy for NSCLC

Learn more about your treatment options for NSCLC by asking your healthcare provider the right questions.

A collection of medication vials and syringes. Immunotherapies for NSCLC are given with an intravenous infusion.

Lung cancer is cancer that begins in the lungs and is one of the most common cancers in the United States. Each year, it’s estimated that more than 228,000 people in the U.S. are diagnosed with lung cancer.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

Treatment for lung cancer is individualized, meaning the recommendations vary from person to person, and take into account numerous factors about the cancer and the person with cancer. There are several categories of therapy that can be used to treat NSCLC. These include chemotherapy, radiation therapy, surgery, targeted therapy, and immunotherapy.

Immune checkpoint inhibitors

Immunotherapy is a newer category of cancer treatment. While treatments like chemotherapy and targeted therapy attack cancer cells directly, immunotherapy works by helping the body’s immune system identify and destroy cancer cells.

The type of immunotherapy drugs used to treat NSCLC are called immune checkpoint inhibitors. Immune checkpoints are proteins that prevent the immune system from attacking healthy cells. Immune checkpoints are found on the surface of healthy cells. In some cases, they are also found on the surface of NSCLC cells.

As the name implies, immune checkpoint inhibitors block these proteins from working. This enables the immune system to identify and destroy cancer cells.

Immune checkpoint inhibitors may be prescribed alone or in combination with other cancer treatments. The immune checkpoint inhibitors used to treat NSCLC are delivered intravenously (via IV).

Questions for your healthcare provider

Before starting immunotherapy for non-small cell lung cancer, it’s a good idea to discuss any questions or concerns you have about treatment. Being informed can help you feel more confident in your treatment decisions and more likely to adhere to your treatment plan. Here are some questions to consider asking:

  • How does immunotherapy work?
  • Will it be given along with another kind of cancer therapy, like chemotherapy?
  • How often will I receive treatment?
  • How long does it take to administer?
  • How long will I be on this therapy?
  • Where will I receive treatment?
  • What side effects can I expect?
  • What is the risk of serious side effects, and how will they be monitored?
  • How will immunotherapy affect my daily life? Will I be tired? Will I be able to work?
  • What can I do to minimize side effects?
  • How will we know if the treatment is working?
  • How often will my progress be monitored?
  • How much will immunotherapy cost?
  • What are my options if immunotherapy doesn’t work?

Remember that every cancer and every patient is different—your healthcare providers are your best source of information about your health and your diagnosis.

Article sources open article sources

American Cancer Society. "Key Statistics for Lung Cancer."
Jennifer Couzin-Frankel. "Cancer Immunotherapy." Science, 2013. Vol. 342, No. 6.
Centers for Disease Control and Prevention. "How Is Lung Cancer Diagnosed and Treated?"
American Cancer Society. "Immunotherapy for Non-Small Cell Lung Cancer."
National Cancer Institute. "Immune Checkpoint Inhibitors."
Edward B. Garon, Matthew D. Hellmann, et al. "Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study." Journal of Clinical Oncology, 2019. Vol. 37, No. 28.
Sun Min Lim, Min Hee Hong, and Hye Ryun Kim. "Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives." Immune Network, 2020. Vol. 20, No. 1.
American Cancer Society. "Treatment Choices for Non-Small Cell Lung Cancer, by Stage."
Memorial Sloan Kettering Cancer Center. "Checkpoint Inhibitors."
Timothy E. Paterick, Nachiket Patel, A. Jamil Tajik, and Krishnaswamy Chandrasekaran. "Improving health outcomes through patient education and partnerships with patients." Baylor University Medical Center Proceedings, 2017. Vol. 30, No. 1.

Featured Content


What Are PD-1 and PD-L1?

Learn how these proteins help people with cancer and their healthcare providers make treatment decisions.

How to Avoid “Caregiver Burnout"

Caregiver burnout is a very real form of physical, emotional and mental exhaustion.

How Diverse Communities Are Impacted by NSCLC

Several disparities, including overall healthcare access, can impact the prevalence of NSCLC in diverse communities.

Lung Cancer and the Risk of Serious Infection

Learn why lung cancer increases your risk of infections—and how to prevent infections from happening.

9 Numbers to Know for Lung Cancer Awareness Month

Statistics that highlight the impact of lung cancer in the United States.